We discussed COH earlier in the week after it was downgraded to a “Sell” by UBS who made some interesting points around the potential for Moderna getting a vaccine approved to treat ~20% of child deafness.
- We see limited upside in COH until some clarity is delivered on Moderna’s mRNA-1547 drug – COH reports on the 19th of this month